ANXA1 and atherosclerosis: ANXA1‐based therapeutics would be more beneficial initially in diseases primarily driven by innate immune cells such as atherosclerosis [8, 64, providing a basis for further research into whether this protein could perhaps also be manipulated within the adaptive immune system.